Hu Chen

Hu Chen

Auto-generated profile, based on publicly available information

Hu Chen

State Key Laboratory of Infectious Disease Vaccine Development, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Science Advances
Verified
Journal Article
Open access
HLHuirong Lin
Huirong Lin
YZYu Zhou
Yu Zhou
JWJiaming Wang
Jiaming Wang
HWHuimeng Wang
Huimeng Wang
TYTianhong Yao
Tianhong Yao
Gang LiuGang Liu
Gang Liu
Indocyanine green was repurposed as iron theranostics for simultaneous detection and treatment of iron-overload disorders.

21 February 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
HCHu Chen
Hu Chen
YXYongfu Xiong
Yongfu Xiong
MTMinglei Teng
Minglei Teng
YLYesen Li
Yesen Li
DZDeliang Zhang
Deliang Zhang
Gang LiuGang Liu
Gang Liu
Transarterial radioembolization (TARE) is a widely utilized therapeutic approach for hepatocellular carcinoma (HCC), however, the clinical implementation is constrained by the stringent preparation conditions of radioembolization agents. Herein, we incorporated the superstable homogeneous iodinated formulation technology (SHIFT), simultaneously utilizing an enhanced solvent form in a carbon dioxide supercritical fluid environment, to encapsulate radionuclides (such as 131I,177Lu, or 18F) with lipiodol for the preparation of radiolipiodol. The resulting radiolipiodol exhibited exceptional stability and ultra-high labeling efficiency (≥99%) and displayed notable intratumoral radionuclide retention and in vivo stability more than 2 weeks following locoregional injection in subcutaneous tumors in mice and orthotopic liver tumors in rats and rabbits. Given these encouraging findings, 18F was authorized as a radiotracer in radiolipiodol for clinical trials in HCC patients, and showed a favorable tumor accumulation, with a tumor-to-liver uptake ratio of ≥50 and minimal radionuclide leakage, confirming the feasibility of SHIFT for TARE applications. In the context of transforming from preclinical to clinical screening, the preparation of radiolipiodol by SHIFT represents an innovative physical strategy for radionuclide encapsulation. Hence, this work offers a reliable and efficient approach for TARE in HCC, showing considerable promise for clinical application (ChiCTR2400087731).

4 April 2021 in Journal of Food Measurement and Characterization
Verified
Journal Article
Closed access
PDF file
LLLiang Liu
Liang Liu
CHChen Hu
Chen Hu
MZMeijia Zou
Meijia Zou
YZYue Zhao
Yue Zhao
XLXin Luo
Xin Luo
XZXianwen Zhang
Xianwen Zhang

15 February 2007 in Key Engineering Materials
Verified
Journal Article
Closed access
PDF file
HCHu Chen
Hu Chen
YWYing Jun Wang
Ying Jun Wang
JWJian Wang
Jian Wang
KNKai Hui Nan
Kai Hui Nan
The processing and properties of porous b-TCP ceramics were investigated. Naphthalene powders used as a pore-making agent. The b-TCP ceramics with a porosity of 75%, a bending strength of 5.3 MPa and pore sizes ranging from 200 ~ 500 µm were obtained. The results showed that the porosity of the ceramics decreased with increasing temperature, while the bending strength increased with increasing temperature. In addition, the phase composition and microstructures of the porous ceramics were examined by x-ray diffraction and scatting electronic microscopy, respectively.

12 May 2022 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
YZYang Zhang
Yang Zhang
Hongwei ChengHongwei Cheng
Hongwei Cheng
HCHu Chen
Hu Chen
PXPeiyao Xu
Peiyao Xu
EREn Ren
En Ren
Gang LiuGang Liu
Gang Liu